US FDA’s Use Of CRLs Hit A High Note In 2022: One-Third Of Novel Agent Decisions Were Not Approvals
Pink Sheet infographic details the 20 complete response letters the US FDA issued for novel agents last year.

Pink Sheet infographic details the 20 complete response letters the US FDA issued for novel agents last year.